The TIGOS trial: A randomized, double-blind phase 3 trial of atigotatug + nivolumab fixed-dose combination with chemotherapy vs atezolizumab with chemotherapy in patients with 1L extensive-stage small cell lung cancer (ES-SCLC).

Authors: Luis G. Paz-Ares, Kenneth John O'Byrne, Melissa Lynne Johnson, Martin Reck, Nicolas Girard, Hidetoshi Hayashi, Caicun Zhou, Vishwanath Suresh Gharpure, Radhika Pisupati, Misena Pacius, Neal E. Ready

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps8127

Source: Full article

---

Abstract

TPS8127